Quantitative proteomics study of protective effects of grape seed procyanidin B2 on diabetic cardiomyopathy in db/db mice

Bioscience, Biotechnology and Biochemistry

Volumn 78, Issue 9, 2014, Pages 1577-1583

  Luan, Si Si ^a   Yu, Fei ^a   Li, Bao Ying ^a   Qin, Rui Jie ^a   Li, Xiao Li ^a   Cai, Qian ^a   Yin, Wen Bin ^a   Cheng, Mei ^a   Gao, Hai Qing ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cardiac fibrosis; Cardiomyopathy; Grape seed procyanidin B2; ITRAQ; Type 2 diabetes mellitus

Indexed keywords

FLAVONOIDS; MOLECULAR BIOLOGY; PROTEINS;

CARDIAC FIBROSIS; CARDIOMYOPATHY; ITRAQ; PROCYANIDINS; TYPE-2 DIABETES;

MAMMALS;

ANTIOXIDANT; BIFLAVONOID; CATECHIN; GRAPE SEED EXTRACT; PROANTHOCYANIDIN; PROCYANIDIN B2; PROTECTIVE AGENT;

ANIMAL; APOPTOSIS; CHEMISTRY; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; EVALUATION STUDY; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY; PROTEOMICS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BIFLAVONOIDS; CATECHIN; DIABETIC CARDIOMYOPATHIES; EVALUATION STUDIES AS TOPIC; GRAPE SEED EXTRACT; MALE; MICE; OXIDATIVE STRESS; PROANTHOCYANIDINS; PROTECTIVE AGENTS; PROTEOMICS;

EID: 84908572663     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1080/09168451.2014.930320     Document Type: Article

References (34)

1. Shaw JE, Sicree RA, Zimmet PZ Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes. Res. Clin. Pract. 2010; 87:4-14.
2. Fang ZY, Prins JB, Marwick TH Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 2004; 25:543-567.
3. Rubler S, Dlugash J, Yuceoglu Y.Z., Kumral T., Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 1972; 30:595-602.
4. Boyer JK, Thanigaraj S, Schechtman K.B., Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normoten-sive patients with diabetes mellitus. Am. J. Cardiol. 2004; 93: 870-875.
5. Asbun J, Villarreal FJ The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2006; 47:693-700.
6. Shizukuda Y, Buttrick PM Oxygen free radicals and heart failure: new insight into an old question. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2002; 283:L237-238.
7. Lee YA, Cho EJ, Yokozama T. Effects of proanthocyanidin preparations on hyperlipidemia and other biomarkers in mouse model of type 2 diabetes. J. Agric. Food. Chem. 2008; 56:7781-7789.
8. Houde V, Grenier D, Chandad F. Protective effects of grape seed proanthocyanidins against oxidative stress induced by lipopoly-saccharides of periodontopathogens. J. Periodontol. 2006; 77: 1371-1379.
9. Shao ZH, Becker LB, VandenHoek T.L., Schumacker PT, Li CQ, Zhao D, Wojcik K., Anderson T, Qin Y, Dey L., Yuan CS. Grape seed proanthocyanidin extract attenuates oxidant injury in cardio-myocytes. Pharmacol. Res. 2003; 47:463-469.
10. Yogalakshmi B, Sreeja S, Geetha R., Radika MK, Anuradha CV. Grape seed proanthocyanidin rescues rats from steatosis: a comparative and combination study with metformin. J. Lipids. 2013; 2013:153897.
11. Li BY, Li XL, Cai Q, Gao H.Q., Cheng M., Zhang JH, Wang JF, Yu F, Zhou RH Induction of lactadherin mediates the apoptosis of endothelial cells in response to advanced glycation end products and protective effects of grape seed procyanidin B2 and res-veratrol. Apoptosis. 2011; 16:732-745.
12. Li BY, Li XL, Gao H.Q., Zhang JH, Cai Q, Cheng M, Lu M. Grape seed procyanid in B2 inhibits advanced glycation end products induced endothelial cell apoptosis through regulating GSK3β phosphorylation. Cell. Biol. Int. 2011; 35:663-669.
13. Yu F, Li BY, Li X.L., Cai Q., Zhang Z, Cheng M, Yin M., Wang JF, Zhang JH, Lu WD, Zhou R.H., Gao HQ. Proteomic analysis of aorta and protective effects of grape seed procyanidin B2 in db/db mice reveal a critical role of milk fat globule epidermal growthfac-tor-8 in diabetic arterial damage. PLoS. One. 2012; 7:e52541.
14. Nunoda S, Genda A, Sugihara N., Nakayama A, Mizuno S, Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart. Vessels. 1985; 1:43-47.
15. Adeghate E, Singh J. Structural changes in the myocardium during diabetes-induced cardiomyopathy. Heart. Fail. Rev. 2014; 19: 15-23.
16. Lee JE, Yi CO, Jeon B.T., Shin HJ, Kim SK, Jung TS, Choi J.Y., Roh GS. Alpha-lipoic acid attenuates cardiac fibrosis in Otsuka Long-Evans Tokushima Fatty rats. Cardiovasc. Diabetol. 2012; 11:111.
17. Cai Q, Li BY, Gao H.Q., Zhang JH, Wang JF, Yu F, Yin M., Zhang Z. Grape seed procyanidin b2 inhibits human aortic smooth muscle cell proliferation and migration induced by advanced glycation end products. Biosci. Biotechnol. Biochem. 2011; 75:1692-1697.
18. Fowlkes V, Clark J, Fix C., Law BA, Morales MO, Qiao X, Ako-Asare K, Goldsmith J.G., Carver W., Murray DB, Goldsmith EC. Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life. Sci. 2013; 92:669-676.
19. Kim J, Sohn E, Kim C.S., Lee YM, Jo K, Kim JS. Effect of KIOM-79 on diabetes-induced myocardial fibrosis in Zucker diabetic fatty rats. Evid. Based. Complement. Alternat. Med. 2013; 2013:547653.
20. Mason RM, Wahab NA Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 2003; 14:1358-1373.
21. Heizmann CW, Fritz G, Schafer BW S100 proteins: structure, functions and pathology. Front. Biosci. 2002; 7:d1356-1368.
22. Gebhardt C, Nemeth J, Angel P., Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 2006; 72: 1622-1631.
23. He H, Li J, Weng S., Li M, Yu Y. S100A11: diverse function and pathology corresponding to different targetproteins. Cell. Biochem. Biophys. 2009; 55:117-126.
24. Ihm SH, Chang K, Kim H.Y., Baek SH, Youn HJ, Seung KB, Kim JH Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic. Res. Cardiol. 2010; 105:399-407.
25. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr. Mol. Med. 2007; 7:711-724.
26. Westermann D, Rutschow S, Jäger S, Linderer A., Anker S, Riad A, Unger T., Schultheiss HP, Pauschinger M, Tschöpe C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes. 2007; 56:641-646.
27. Sassoli C, Chellini F, Pini A., Tani A, Nistri S, Nosi D., Zecchi-Orlandini S, Bani D, Formigli L. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling. PLoS. One. 2013; 8: e63896.
28. Feng XH, Derynck R. Specificity and versatility in TGF-beta signaling through Smads. Annu. Rev. Cell. Dev. Biol. 2005; 21:659-693.
29. Samarakoon R, Overstreet JM, Higgins PJ TGF-β signaling in tissue fibrosis: Redox controls, target genes and therapeutic opportunities. Cell. Signal. 2013; 25:264-268.
30. Shen X, Yang Y, Xu Y., Xu L, Fang T. Protective effect of TGF-beta-Smads signal-based oxymatrine on myocardial fibrosis induced by acute myocardial infarction in rats. Zhongguo Zhong Yao Za Zhi. 2012; 37:632-636.
31. Ikegawa S. Expression, regulation and function of asporin, a susceptibility gene in common bone and joint diseases. Curr. Med. Chem. 2008; 15:724-728.
32. Ikegawa S. Asporin, a susceptibility gene for osteoarthritis. Clin. Calcium. 2006; 16:1548-1552.
33. Tian W, Zheng S, Jiang X.Z., Wu CA, Wang N, Zhao DH. Asporin, a candidate protein for treatment of disc degenerative disease. Chin. Med. J (Engl). 2013; 126:369-372.
34. Barallobre-Barreiro J., Didangelos A, Schoendube F.A., Drozdov I., Yin X, Fernandez-Caggiano M, Willeit P, Puntmann V.O., Aldama-Lopez G, Shah AM, Domenech N, Mayr M. Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury. Circulation. 2012; 125: 789-802.